- Report
- January 2024
- 200 Pages
Global
From €3982EUR$4,150USD£3,430GBP
- Report
- February 2021
- 360 Pages
United States
From €2303EUR$2,400USD£1,983GBP
- Report
- February 2019
- 105 Pages
Global
From €1238EUR$1,290USD£1,066GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €480EUR$500USD£413GBP
- Report
- January 2019
- 35 Pages
Global
From €959EUR$1,000USD£826GBP
- Report
- February 2024
- 87 Pages
Global
From €3500EUR$3,908USD£3,120GBP
- Report
- November 2023
- 35 Pages
Global
From €3541EUR$3,690USD£3,049GBP
Kaletra (lopinavir/ritonavir) is a combination antiretroviral medication used to treat HIV/AIDS. It is a protease inhibitor, which works by blocking the action of the HIV protease enzyme, preventing the virus from multiplying. Kaletra is usually prescribed in combination with other antiretroviral drugs, as part of a highly active antiretroviral therapy (HAART) regimen. Kaletra is available in both tablet and liquid form, and is taken twice daily.
Kaletra is one of the most commonly prescribed antiretroviral medications for HIV/AIDS, and is widely used in both developed and developing countries. It is generally well tolerated, with few side effects, and is considered to be an effective treatment for HIV/AIDS.
The Kaletra market is highly competitive, with several major pharmaceutical companies producing and marketing the drug. Companies in the market include AbbVie, Mylan, Teva Pharmaceuticals, and Cipla. Show Less Read more
